Bruce Montgomery - Xencor Director
| XNCR Stock | USD 23.93 2.99 14.28% |
Director
Dr. A. Bruce Montgomery M.D. is the Lead Independent Director of the company. Dr. Montgomery joined our Board of Directors in March 2015. Dr. Montgomery has more than 25 years of drug development, operations and financing experience, including positions at Genentech, Inc., Pathogenesis Corporationrationration, Corus Pharma, and Gilead Sciences, Inc. He is currently Chief Executive Officer and a member of the board of directors of Avalyn Pharma, a private biotechnology company which he joined in 2017. From 2011 to 2016, he was Chief Executive Officer and a member of the board of directors of Cardeas Pharma, a private biotechnology company that he founded in 2010. From August 2006 to May 2011, Dr. Montgomery served as Senior Vice President of Gilead Sciences, Inc. and prior to that, served for six years as Chief Executive Officer of Corus Pharma, a specialized biotechnology company that he founded, which was acquired by Gilead in 2006. While at Gilead, Dr. Montgomery successfully led the development of Cayston as a treatment for cystic fibrosis patients. Dr. Montgomery also served as Executive Vice President of Research and Development at PathoGenesis Corporation until its acquisition by Chiron Corporation in 2000. He has served as a board member for ZymoGenetics, Inc. and is currently on the board of Alder Biopharmaceuticals and Cytodyn, Inc. Dr. Montgomery is a boardcertified internist and pulmonologist since 2015.
| Age | 64 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 465 North Halstead Street, Pasadena, CA, United States, 91107 |
| Phone | 626 305 5900 |
| Web | https://www.xencor.com |
Xencor Management Efficiency
The company has return on total asset (ROA) of (0.0955) % which means that it has lost $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1808) %, meaning that it created substantial loss on money invested by shareholders. Xencor's management efficiency ratios could be used to measure how well Xencor manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/02/2024, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to grow to -0.15. At this time, Xencor's Non Current Assets Total are relatively stable compared to the past year. As of 05/02/2024, Non Currrent Assets Other is likely to grow to about 125.4 M, while Other Current Assets are likely to drop slightly above 12.1 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Christine Seidman | Merck Company | 68 | |
| Rochelle Lazarus | Merck Company | 71 | |
| Leslie Brun | Merck Company | 68 | |
| Kathy Warden | Merck Company | 49 | |
| Wilfred OGara | LSI Industries | 60 | |
| Peter Wendell | Merck Company | 70 | |
| Robert Kidder | Merck Company | 71 | |
| Gary Kreider | LSI Industries | 78 | |
| Thomas Glocer | Merck Company | 61 | |
| Carlos Represas | Merck Company | 72 | |
| John Noseworthy | Merck Company | 66 | |
| Craig Thompson | Merck Company | 64 | |
| Paul Rothman | Merck Company | 63 | |
| William Harrison | Merck Company | 70 | |
| Thomas Cech | Merck Company | 72 | |
| Pamela Craig | Merck Company | 64 | |
| Mary Coe | Merck Company | 54 | |
| Robert Steele | LSI Industries | 62 | |
| Amy Hanson | LSI Industries | N/A | |
| Patricia Russo | Merck Company | 68 | |
| Wendell Weeks | Merck Company | 59 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0955 |
Xencor Inc Leadership Team
Elected by the shareholders, the Xencor's board of directors comprises two types of representatives: Xencor inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xencor. The board's role is to monitor Xencor's management team and ensure that shareholders' interests are well served. Xencor's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xencor's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edgardo Baracchini, Chief Business Officer | ||
| Bart Cornelissen, Senior CFO | ||
| Bruce Montgomery, Director | ||
| Bassil Dahiyat, Co-Founder, CEO and President and Director | ||
| John Kuch, VP of Fin. | ||
| Ellen Feigal, Director | ||
| Charles Liles, Associate Relations | ||
| Debra Zack, Vice President - Clinical Development | ||
| Nancy MD, Executive Officer | ||
| Dane CFA, Senior Strategy | ||
| Mark Lotz, Vice President - Regulatory Affairs | ||
| Eric Kowack, Senior Management | ||
| Celia JD, General VP | ||
| Lloyd Rowland, Chief Compliance Officer, Sr. VP, General Counsel and Secretary | ||
| Richard Ranieri, Director | ||
| John Desjarlais, Chief Scientific Officer and Sr. VP of Research | ||
| Kirk RAC, Senior Assurance | ||
| Jeremy Grunstein, Vice President of Business Development | ||
| Bruce Carter, Independent Chairman of the Board | ||
| Paul Foster, Chief Medical Officer | ||
| Robert Baltera, Independent Director | ||
| Jennifer Sandoz, Vice Resources | ||
| Wayne Saville, Vice President - Clinical Oncology | ||
| Yujiro Hata, Director | ||
| Kurt Gustafson, Director | ||
| Kevin Gorman, Independent Director |
Xencor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xencor a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0955 | ||||
| Profit Margin | (0.75) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 769.9 M | ||||
| Shares Outstanding | 61.65 M | ||||
| Shares Owned By Insiders | 0.94 % | ||||
| Shares Owned By Institutions | 99.06 % | ||||
| Number Of Shares Shorted | 6.22 M | ||||
| Price To Earning | 69.81 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| CRM | Salesforce | |
| GOOG | Alphabet Inc Class C |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xencor Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Xencor Inc information on this page should be used as a complementary analysis to other Xencor's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Xencor Stock analysis
When running Xencor's price analysis, check to measure Xencor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xencor is operating at the current time. Most of Xencor's value examination focuses on studying past and present price action to predict the probability of Xencor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xencor's price. Additionally, you may evaluate how the addition of Xencor to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Xencor's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xencor. If investors know Xencor will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xencor listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 2.782 | Quarterly Revenue Growth 1.068 | Return On Assets (0.1) | Return On Equity (0.18) |
The market value of Xencor Inc is measured differently than its book value, which is the value of Xencor that is recorded on the company's balance sheet. Investors also form their own opinion of Xencor's value that differs from its market value or its book value, called intrinsic value, which is Xencor's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xencor's market value can be influenced by many factors that don't directly affect Xencor's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xencor's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xencor is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xencor's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.